Novo Nordisk shares dive 9% after heart medicine fails trial
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday. This story matters for Finance & Markets readers tracking bond. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BondNews curates and briefs the finance & markets stories that matter. Our editorial policy →